Table 4.

Multivariate analysis for mortality within 5 years after HTX

Variable	Hazard ratio	95% CI	P value
Administration of ivabradine after HTX (in total)	0.25	0.09–0.70	< 0.01*
Recipient age (years)	1.01	0.96–1.05	0.80
Donor age (years)	1.00	0.96–1.03	0.88
Transplant sex mismatch (in total)	1.30	0.55–3.10	0.55
Ischemic time (min)	1.00	0.99–1.01	0.89

CI confidence interval, HTX heart transplantation

*Statistically significant (P < 0.05)